What is claimed is:

1. A compound of the formula below:



,

wherein n is 1 or 2; and

R1 is H or -CH_3,

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula below:



,

wherein n is 1 or 2; and

R1 is H or -CH_3,

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 or 2, wherein n is 1, or a pharmaceutically acceptable salt thereof.

4. The compound according to claim 1 or 2, wherein n is 2, or a pharmaceutically acceptable salt thereof.

5. The compound according to claim 1 or 2, wherein R1 is H, or a pharmaceutically acceptable salt thereof.

6. The compound according to claim 1 or 2, wherein R1 is -CH_3, or a pharmaceutically acceptable salt thereof.

7. The compound according to claim 2, which is



,

or a pharmaceutically acceptable salt thereof.

8. A compound of the formula below



,

or a pharmaceutically acceptable salt thereof.

9. The compound according to claim 2, which is provided as a mono or di hydrochloride addition salt, methylsulfonic acid addition salt, or a 4-methylbenzenesulfonic acid addition salt.

10. The compound according to claim 8, which is (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-amine 4-methylbenzenesulfonate.

11. A compound, which is (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-amine 4-methylbenzenesulfonate in crystalline form characterized by an X-ray powder diffraction pattern obtained from a CuKα source (λ=1.54056 Å), which comprises peaks at:

a) 18.6, 19.1, 21.0, 21.9, and 22.4 +/- 0.2° in 2 theta, or

b) 17.6, 11.0, 16.8, 18.6, 19.1, 21.0, 21.9, 22.4 and 26.1 +/- 0.2° in 2 theta.

12. The compound according to claim 8, which is (E)-3-fluoro-2-[[2-(4-,methoxy-1-piperidyl)pyrimidin-5-yl]oxymethyl]prop-2-en-1-amine dihydrochloride.

13. A pharmaceutical composition comprising the compound according to any one of claims 1, 2, or 7 to 12 and a pharmaceutically acceptable carrier, diluent or excipient.

14. Use of the pharmaceutical composition according to claim 13 in the manufacture of a medicament for treating a patient in need of treatment for non-alcoholic steatohepatitis.

5